December 23, 2024 09:27 AM EST
Pharma
FDA+

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Jaimy Lee

Deputy Editor

Eli Lil­ly’s weight loss jug­ger­naut Zep­bound has been ap­proved in the US to treat sleep ap­nea, and the la­bel ex­pan­sion could open the door to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

'No mir­a­cles': What Re­gen­eron's George Yan­copou­los re­al­ly thinks of AI

RFK Jr. says he’ll di­vest in­ter­ests in CRISPR Ther­a­peu­tics if con­firmed for HHS chief

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times